Individual differences in genes and proteins can allow a disease to develop, grow, and spread in one person but not another, and also dictate how individuals respond to treatments. Oregon Health & Science University and the U.S. Department of Energy's Pacific Northwest National Laboratory launched the Precision Medicine Innovation Co-Laboratory in February 2018 to integrate patient-specific differences in diagnosis and clinical care. The scope of the joint venture was expanded to include basic science research programs and it was renamed the Pacific northwest bioMedical Innovation Co-laboratory (PMedIC) in January 2022. PMedIC aims to generate, interpret, and integrate multidimensional omics and imaging data with clinical results to gain mechanistic understanding of disease and develop innovative therapies.
PMedIC leadership act as a clearinghouse for researchers, matching them to subject matter experts at both OHSU and PNNL. They also assist in putting together teams for the development of joint proposals, help investigators identify sources of funding for pilot projects, and assist with proposal management.
New insights from PMedIC's approach will inform clinical trials, leading to more customized treatments and better patient outcomes.
PMedIC Co-Director Dr. Karin Rodland talks about the promise of precision medicine: "I dream of a day when no one has to die because of cancer."
Hear how OHSU's Knight Cancer Institute is personalizing medicine for its patients.
Dr. Karin Rodland talks about identifying the proteins in ovarian tumors—the first step to targeting drugs for specific individuals.
Meet the scientists of OHSU.